Boehringer Ingelheim’s Cyltezo (adalimumab-adbm) has been approved as the first US interchangeable biosimilar to Humira, and only the second interchangeable biosimilar overall, by the US Food and Drug Administration.
The biosimilar – which was initially approved by the FDA in August 2017 – is currently scheduled to be among...






